End-of-day quote
Shanghai S.E.
06:00:00 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
10.68
CNY
|
+0.19%
|
|
-4.30%
|
-14.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
20,015
|
-
|
-
|
Enterprise Value (EV)
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
20,015
|
20,015
|
20,015
|
P/E ratio
|
22.5
x
|
24.3
x
|
18.7
x
|
14.3
x
|
16.4
x
|
13
x
|
11.4
x
|
9.98
x
|
Yield
|
1.55%
|
1.08%
|
1.17%
|
1.59%
|
1.45%
|
1.73%
|
1.97%
|
2.06%
|
Capitalization / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.16
x
|
1.06
x
|
1
x
|
EV / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.16
x
|
1.06
x
|
1
x
|
EV / EBITDA
|
7.3
x
|
7.55
x
|
6.71
x
|
4.91
x
|
6.11
x
|
6.83
x
|
5.82
x
|
5.26
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.94
x
|
2.45
x
|
2.05
x
|
1.66
x
|
1.69
x
|
1.34
x
|
1.22
x
|
1.11
x
|
Nbr of stocks (in thousands)
|
1,938,033
|
1,931,529
|
1,870,352
|
1,865,499
|
1,864,280
|
1,874,019
|
-
|
-
|
Reference price
2 |
10.35
|
13.91
|
12.84
|
11.29
|
12.43
|
10.68
|
10.68
|
10.68
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,980
|
13,522
|
15,904
|
17,143
|
16,646
|
17,300
|
18,826
|
20,113
|
EBITDA
1 |
2,749
|
3,559
|
3,578
|
4,285
|
3,794
|
2,930
|
3,436
|
3,806
|
EBIT
1 |
2,187
|
2,973
|
2,983
|
3,480
|
3,507
|
3,659
|
4,186
|
4,780
|
Operating Margin
|
18.26%
|
21.99%
|
18.76%
|
20.3%
|
21.07%
|
21.15%
|
22.24%
|
23.77%
|
Earnings before Tax (EBT)
1 |
2,178
|
2,950
|
2,952
|
3,456
|
3,466
|
3,632
|
4,160
|
4,743
|
Net income
1 |
894.3
|
1,120
|
1,328
|
1,503
|
1,443
|
1,535
|
1,748
|
1,997
|
Net margin
|
7.47%
|
8.29%
|
8.35%
|
8.77%
|
8.67%
|
8.87%
|
9.29%
|
9.93%
|
EPS
2 |
0.4607
|
0.5728
|
0.6858
|
0.7921
|
0.7565
|
0.8200
|
0.9400
|
1.070
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1600
|
0.1500
|
0.1500
|
0.1800
|
0.1800
|
0.1850
|
0.2100
|
0.2200
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
8.98%
|
10.4%
|
11.5%
|
12.2%
|
11%
|
10.4%
|
10.8%
|
11.1%
|
ROA (Net income/ Total Assets)
|
-
|
4.18%
|
4.48%
|
4.5%
|
4%
|
5.33%
|
5.57%
|
6.4%
|
Assets
1 |
-
|
26,798
|
29,630
|
33,417
|
36,047
|
28,777
|
31,409
|
31,200
|
Book Value Per Share
2 |
5.340
|
5.680
|
6.250
|
6.800
|
7.370
|
8.000
|
8.750
|
9.590
|
Cash Flow per Share
2 |
1.190
|
1.550
|
1.320
|
2.060
|
2.110
|
2.310
|
2.060
|
2.170
|
Capex
1 |
701
|
781
|
1,512
|
1,145
|
1,115
|
913
|
1,116
|
975
|
Capex / Sales
|
5.85%
|
5.78%
|
9.51%
|
6.68%
|
6.7%
|
5.28%
|
5.93%
|
4.85%
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Last Close Price
10.68
CNY Average target price
14.7
CNY Spread / Average Target +37.64% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.08% | 2.75B | | +59.97% | 840B | | +38.38% | 621B | | -6.18% | 354B | | +15.61% | 319B | | +8.44% | 297B | | +12.68% | 237B | | +14.40% | 221B | | +0.04% | 220B | | +9.68% | 169B |
Other Pharmaceuticals
|